HomeCompareCASBF vs STAG

CASBF vs STAG: Dividend Comparison 2026

CASBF yields 51.81% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CASBF wins by $11.7K in total portfolio value
10 years
CASBF
CASBF
● Live price
51.81%
Share price
$3.86
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.0K
Annual income
$7.71
Full CASBF calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — CASBF vs STAG

📍 CASBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCASBFSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CASBF + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CASBF pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CASBF
Annual income on $10K today (after 15% tax)
$4,404.15/yr
After 10yr DRIP, annual income (after tax)
$6.55/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, STAG beats the other by $386.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CASBF + STAG for your $10,000?

CASBF: 50%STAG: 50%
100% STAG50/50100% CASBF
Portfolio after 10yr
$24.2K
Annual income
$234.96/yr
Blended yield
0.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

CASBF
No analyst data
Altman Z
2.6
Piotroski
4/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CASBF buys
0
STAG buys
0
No recent congressional trades found for CASBF or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCASBFSTAG
Forward yield51.81%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0.3%
Portfolio after 10y$30.0K$18.3K
Annual income after 10y$7.71$462.22
Total dividends collected$6.0K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CASBF vs STAG ($10,000, DRIP)

YearCASBF PortfolioCASBF Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$13,291$2,590.67$10,665$345.09+$2.6KCASBF
2$15,830$1,608.96$11,364$357.70+$4.5KCASBF
3$17,834$895.50$12,098$370.43+$5.7KCASBF
4$19,553$471.42$12,869$383.28+$6.7KCASBF
5$21,164$241.53$13,677$396.23+$7.5KCASBF
6$22,767$122.16$14,524$409.27+$8.2KCASBF
7$24,422$61.41$15,411$422.41+$9.0KCASBF
8$26,163$30.78$16,339$435.61+$9.8KCASBF
9$28,010$15.41$17,311$448.89+$10.7KCASBF
10$29,978$7.71$18,327$462.22+$11.7KCASBF

CASBF vs STAG: Complete Analysis 2026

CASBFStock

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Full CASBF Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this CASBF vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CASBF vs SCHDCASBF vs JEPICASBF vs OCASBF vs KOCASBF vs MAINCASBF vs PLDCASBF vs EQRCASBF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.